Previous close | 121.20 |
Open | 121.80 |
Bid | 122.40 x 0 |
Ask | 123.00 x 0 |
Day's range | 120.60 - 122.40 |
52-week range | 91.00 - 122.40 |
Volume | |
Avg. volume | 4 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 25 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Merck & Co., Inc. ( NYSE:MRK ) just released its quarterly report and things are looking bullish. The company beat...
On Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the consensus estimate of $15.2 billion. Excluding the impact of foreign exchange, sales increased 24%. Merck reported adjusted EPS of $2.07, up 48%Y/Y, beating the consensus of $1.88. Merck’s pharmaceutical unit booked $14.01 billion in revenue during the first quarter, up 10% Y/Y. Related: Merck’s $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease. Me
Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024. Stock rises in pre-market.